| The Merck Manual of Diagnosis and Therapy
| [0005]
[0011]
|
| Drugs of the future
| [0023]
|
| Arthritis & Rheumatology
| [0024]
|
| The Merck Manual of Diagnosis and Therapy
| [0071]
[0072]
[0073]
[0075]
[0078]
|
| 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
| [0345]
|
| Enzymatic Determination of Total Serum Cholesterol
| [0345]
|
| HDL-C: Role as a risk modifier
| [0345]
|
| Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
| [0345]
|
| Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
| [0345]
|
| Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
| [0345]
|
| Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range
| [0345]
|
| Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI)
| [0345]
|
| Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
| [0345]
|
| Cardiovascular disease - the silent killer in rheumatoid arthritis
| [0345]
|
| Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study
| [0345]
|
| Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
| [0345]
|
| Search for an Optimal Atherogenic Lipid Risk Profile: From the Framingham Study
| [0345]
|
| Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial
| [0345]
|
| CRP-Marker or Maker of Cardiovascular Disease?
| [0345]
|
| Back to the Future: Oral targeted therapy for RA and other autoimmune diseases
| [0345]
|
| JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
| [0345]
|
| Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein
| [0345]
|
| Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
| [0345]
|
| Measurement of low-density-lipoprotein cholesterol in serum: a status report
| [0345]
|
| Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
| [0345]
|
| Low-Density-Lipoprotein Particle Size Predicts a Poor Outcome in Patients with Atherothrombotic Stroke
| [0345]
|
| The Merck Manual of Diagnosis and Therapy
| [0345]
|
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
| [0345]
|
| Greene's Protective Groups in Organic Synthesis
| [0345]
|
| Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD
| [0345]
|